Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Vfend Antifungal Has Broader Indication, Doses Than Merck’s Cancidas

Executive Summary

Pfizer's Vfend has a broader indication and more dosing options than Merck's Cancidas upon FDA approval of the Pfizer antifungal

You may also be interested in...



Pfizer Vfend approval

Pfizer's Vfend receives supplemental approval for treatment of esophageal candidiasis Nov. 14. Vfend (voriconazole) was initially approved for primary invasive aspergillosis therapy in May 2002 (1"The Pink Sheet" June 3, 2002, p. 10)...

Pfizer Vfend approval

Pfizer's Vfend receives supplemental approval for treatment of esophageal candidiasis Nov. 14. Vfend (voriconazole) was initially approved for primary invasive aspergillosis therapy in May 2002 (1"The Pink Sheet" June 3, 2002, p. 10)...

Pfizer Vfend Sets New Efficacy Standard In Invasive Aspergillosis, FDA Says

Pfizer's Vfend sets a "new standard" for non-inferiority trials in invasive aspergillosis, FDA says in review documents for the antifungal

Related Content

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel